PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy
Plasma PDLpfeRNAs are predictors of treatment response of unresectable MPM patients treated with Durva-CP as first-line therapy to select optimal candidates and monitor the developed resistance.
Authors
- Kristen Rodgers (ORCID: https://orcid.org/0000-0003-4302-9578)
- Andrei Gurau (ORCID: https://orcid.org/0000-0003-4610-721X)
- Valsamo Anagnostou (ORCID: https://orcid.org/0000-0001-9480-3047)
- Patrick M. Forde (ORCID: https://orcid.org/0000-0001-6925-6344)
- James R. Eshleman (ORCID: https://orcid.org/0000-0002-9274-8459)
- Joshua Choi
- Suguru Yamauchi (ORCID: https://orcid.org/0000-0001-5418-7112)
- Peng Huang (ORCID: https://orcid.org/0000-0002-2152-9152)
- Charles Conover Talbot
- Malcolm V. Brock
- Yuping Mei
- Kaitlyn Ecoff
Institutions
- Kennedy Krieger Institute (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Juntendo University (JP)
- Johns Hopkins Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Non-coding RNA Research
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.ncrna.2025.02.003
- Citations
- 2
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Foundation for the National Institutes of Health
- Promotion and Mutual Aid Corporation for Private Schools of Japan
- National Institutes of Health